Amarin Corp. PLC's First Amendment legal victory on Vascepa (icosapent ethyl) may intensify pressure on FDA to develop new guidance and regulations governing off-label promotion before its hand is further forced by more adverse court rulings and Congress.
In an Aug. 7 opinion, U.S. District Judge Paul Engelmayer of the Southern District of New York ruled that Amarin...